Abstract: An ion channel blocker for treatment and/or prevention of hepatic fibrosis is provided. Based on the fact that the activation of hepatic stellate cells is an important link in anti-hepatic fibrosis, it is found that gliclazide has the effect of inhibiting the activation of hepatic stellate cells by in vitro and in vivo experiments. Further exploration reveals that gliclazide mainly inhibits the activation of hepatic stellate cells by inhibiting autophagy pathways, and thus the gliclazide can be used to prepare medicaments for treatment and/or prevention of hepatic fibrosis.

Abstract: An application of a channel blocker in preparation of drugs for treating and/or preventing liver fibrosis is provided, belonging to the field of biomedical technology. A new use of phenytoin sodium is provided. It is demonstrated that at the cell level, the phenytoin sodium can improve liver fibrosis by regulating autophagy and thus affecting the activation of hepatic stellate cells. In this situation, the efficacy of the phenytoin sodium on liver fibrosis is verified at the animal level by establishing a disease model, and the phenytoin sodium can be used to prepare drugs for treating and/or preventing liver fibrosis.

Abstract: An application of potassium ion (K+) channel blocker in preparation of drugs for treating liver fibrosis is provided, which relates to the field of medical technologies. The K+ channel blocker is sotalol, the sotalol is originally used as an antiarrhythmic drug in clinic and has a property of inhibiting K+ channels. Experiments show that sotalol can effectively inhibit liver fibrosis and reduce expression of fibrosis-related protein alpha-smooth muscle actin (?-SMA), specifically by regulating expression and/or function of autophagy and epithelial-mesenchymal transition (EMT) molecules to achieve inhibition of hepatic stellate cell (HSC) fibrosis, so as to provide a new drug choice for clinical treatment of the liver fibrosis.